Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

Fintel reports that on March 17, 2025, William Blair initiated coverage of Butterfly Network (NYSE:BFLY) with a Outperform ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

In a report released today, Ross Sparenblek from William Blair maintained a Buy rating on MSA Safety (MSA – Research Report). The company’s ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as president and CEO, effective immediately, to succeed Greg Brown.

Overall, Palantir has had a solid start to 2025. Its growth numbers look impressive, and its AI platform is gaining traction across industries. Yet not everyone is convinced. Some ...

Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and negative factors. Uncover insightful assessments of a stock's market performance and potential with ...